Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplontersen and ALXN2220 in ATTR-CM
NCT07608354Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Primary completion
- Feb 2029
- Countries
- 10
01
Overview
A Phase 2 trial of cliramitug in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by AstraZeneca. Started Jun 2026; status: active, not recruiting.
02
Drugs
cliramitug
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07608354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608354.